Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) – Pipeline Review, H2 2017’, provides in depth analysis on Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Infectious Disease, Immunology, Central Nervous System, Metabolic Disorders and Respiratory under development targeting Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23)

The report reviews Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics and enlists all their major and minor projects

The report assesses Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Astex Pharmaceuticals Inc

AstraZeneca Plc

Bayer AG

Cyclacel Pharmaceuticals Inc

Eli Lilly and Co

Jyant Technologies Inc

MEI Pharma Inc

Selvita SA

Tolero Pharmaceuticals Inc

Vichem Chemie Research Ltd

ViroStatics srl

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC

2.7.11.22 or EC

2.7.11.23) - Overview 8

Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC

2.7.11.22 or EC

2.7.11.23) - Therapeutics Development 9

Products under Development by Stage of Development 9

Products under Development by Therapy Area 10

Products under Development by Indication 11

Products under Development by Companies 15

Products under Development by Universities/Institutes 21

Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC

2.7.11.22 or EC

2.7.11.23) - Therapeutics Assessment 23

Assessment by Mechanism of Action 23

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC

2.7.11.22 or EC

2.7.11.23) - Companies Involved in Therapeutics Development 27

Astex Pharmaceuticals Inc 27

AstraZeneca Plc 27

Bayer AG 28

Cyclacel Pharmaceuticals Inc 29

Eli Lilly and Co 30

Jyant Technologies Inc 31

MEI Pharma Inc 31

Selvita SA 32

Tolero Pharmaceuticals Inc 32

Vichem Chemie Research Ltd 33

ViroStatics srl 33

Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC

2.7.11.22 or EC

2.7.11.23) - Drug Profiles 34

alvocidib hydrochloride - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

alvocidib hydrochloride - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

AT-7519 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

atuveciclib - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

AZ-5576 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

AZD-4573 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

BAY-1251152 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

CCT-68127 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

CYC-065 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

FIT-039 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

LY-2857785 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

sapacitabine + seliciclib - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

SEL-120 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

seliciclib - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Small Molecule to Inhibit CDK9 for Breast Cancer - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Small Molecule to Inhibit CDK9 for Inflammation and Oncology - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Small Molecule to Inhibit CDK9 for Multiple Myeloma - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Small Molecule to Inhibit Cyclin Dependent Kinase 9 for Oncology - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Small Molecules to Inhibit CDK9 for HIV-1 Infection - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Small Molecules to Inhibit CDK9 for Inflammatory Pain and Rheumatoid Arthritis - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Small Molecules to Inhibit CDK9 for Oncology - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

TG-02 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

TP-1287 - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

voruciclib - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

VS-2370 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC

2.7.11.22 or EC

2.7.11.23) - Dormant Products 78

Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC

2.7.11.22 or EC

2.7.11.23) - Discontinued Products 80

Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC

2.7.11.22 or EC

2.7.11.23) - Product Development Milestones 81

Featured News & Press Releases 81

Oct 23, 2017: Tolero Pharma To Present Preclinical Data for Cancer Drug Candidate TP-1287 for Myc-dependent Triple Negative Breast Cancer 81

Oct 05, 2017: Tolero Pharmaceuticals To Provide Update On alvocidib At 9th International Conference On Leukemia And Hematologic Oncology 81

Sep 26, 2017: Powerful Drug Combo Gangs Up to Tackle Triple-Negative Breast Cancer 82

Aug 07, 2017: Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression 83

Jun 21, 2017: Tolero Pharmaceuticals to Expand Enrollment of Phase II Study of Alvocidib in MCL-1-Dependent AML into Europe 84

Jun 15, 2017: Tolero Pharmaceuticals to Present Supportive Preclinical Data for Investigational CDK Inhibitor Alvocidib at European Hematology Association Annual Meeting 84

May 08, 2017: Tolero Pharmaceuticals Appoints Robert Imani Vice President, Drug Development 85

Apr 05, 2017: Tolero Pharmaceuticals Presents Preclinical Data on CDK9 Inhibitor Alvocidib at AACR 2017 86

Apr 05, 2017: Tolero Pharmaceuticals Presents Preclinical Data on Alvocidib's Prodrug, TP-1287, at AACR 2017 86

Apr 02, 2017: Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways 87

Mar 07, 2017: Cyclacels CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI 88

Nov 15, 2016: Tolero Pharmaceuticals to Present Progress of Leukemia Program at the 58th ASH Annual Meeting and Exposition 88

Sep 06, 2016: Cyclacel's CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical Data Presented at Childhood Cancer 2016 88

Sep 06, 2016: Cyclacel Pharmaceuticals presents preclinical data on CCT68127 at Childhood Cancer 2016 89

Aug 02, 2016: Cyclacel CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data Published by Independent Academic Researchers 90

Appendix 91

Methodology 91

Coverage 91

Secondary Research 91

Primary Research 91

Expert Panel Validation 91

Contact Us 91

Disclaimer 92

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Indications, H2 2017 11

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 14

Number of Products under Development by Companies, H2 2017 15

Products under Development by Companies, H2 2017 16

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 19

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 20

Number of Products under Investigation by Universities/Institutes, H2 2017 21

Products under Investigation by Universities/Institutes, H2 2017 22

Number of Products by Stage and Mechanism of Actions, H2 2017 23

Number of Products by Stage and Route of Administration, H2 2017 25

Number of Products by Stage and Molecule Type, H2 2017 26

Pipeline by Astex Pharmaceuticals Inc, H2 2017 27

Pipeline by AstraZeneca Plc, H2 2017 28

Pipeline by Bayer AG, H2 2017 29

Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017 30

Pipeline by Eli Lilly and Co, H2 2017 31

Pipeline by Jyant Technologies Inc, H2 2017 31

Pipeline by MEI Pharma Inc, H2 2017 31

Pipeline by Selvita SA, H2 2017 32

Pipeline by Tolero Pharmaceuticals Inc, H2 2017 32

Pipeline by Vichem Chemie Research Ltd, H2 2017 33

Pipeline by ViroStatics srl, H2 2017 33

Dormant Products, H2 2017 78

Dormant Products, H2 2017 (Contd..1), H2 2017 79

Discontinued Products, H2 2017 80

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Top 10 Indications, H2 2017 11

Number of Products by Stage and Mechanism of Actions, H2 2017 23

Number of Products by Routes of Administration, H2 2017 24

Number of Products by Stage and Routes of Administration, H2 2017 24

Number of Products by Stage and Molecule Type, H2 2017 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports